Associated tags: Therapy, News, Pain, Health, Anxiety, Weight loss, Safety, Sleep, CPG, Cannabinoid, Chemistry, Food, Coffee, Wellness, CBG, Antioxidant, Aspirin, Vitamin C, CBN, Beauty, Global health, CBD, Caffeine, Probiotic
Locations: CALIFORNIA, BIO
Retrieved on:
Thursday, February 29, 2024
Well,
SAN,
Mental health,
Woman,
Fortune 500,
Caregiver,
Nutrition,
Research,
Health,
Vitamin,
Female,
CPG,
Global health,
Food science,
Cannabinoid,
Harvard Business Review,
Empathy,
McKinsey & Company,
Wellness,
Health equity,
Science,
Public,
Management SAN FRANCISCO, Feb. 29, 2024 /PRNewswire/ -- Nalu Bio, a biotech company that is expanding health and wellness solutions through the development of no-high, chemistry-derived cannabinoid CPG ingredients, products, and therapeutic applications, proudly announces the appointment of Dondeena Bradley to its board of directors. With a distinguished career guiding health and wellness strategy, research and development, and wellbeing and nutrition-based innovations for the top global CPG companies, Dondeena brings invaluable expertise to drive an industry shift comparable to the introduction of vitamins 70 years ago—all while while closing the women's wellness gap—a $1 trillion opportunity to improve lives and economies globally.1
Key Points:
- "Dondeena brings valuable insights into CPG solution development and the pivotal stage for global health and wellness leaders' adoption of cannabinoids, making her an invaluable addition to our board," stated Caitlyn Krebs, Co-founder and CEO of Nalu Bio.
- Dondeena joins Nalu Bio as the third female board member, including co-founders Caitlyn Krebs (CEO) and Phyllis Whiteley (Chairman of the Board), who collectively bring decades of pharmaceutical and healthcare experience that drive impact.
- With Dondeena Bradley on its board, Nalu Bio is poised to lead the way in reshaping the future of consumer health and wellness.
- As the first company to offer AI-powered combinations of cannabinoids and bioactives, Nalu Bio continues to drive advancements designed to impact global CPG companies' innovation pipelines.
Retrieved on:
Thursday, February 8, 2024
Partnership,
Coffee,
Anxiety,
Traction,
SAN,
Vitamin,
Science,
AI,
PIPA,
Academic Medicine (journal),
Clinical trial,
Sleep,
Pain,
Safety,
Food,
Probiotic,
Caffeine,
Wellness,
Chemistry,
Cannabinoid,
CBD,
Global health,
Beauty,
CBN,
Vitamin C,
Health,
Aspirin,
Antioxidant,
CPG,
CBG,
Medical device SAN FRANCISCO, Feb. 8, 2024 /PRNewswire/ -- Nalu Bio, a biotech company specializing in no-high, chemistry-derived cannabinoids to address the top health and wellness challenges, today announced a first-of-its-kind partnership with PIPA, AI leader in Nutrition, Health and Wellness innovation to bring AI-enabled combinations of cannabinoids and bioactives to consumer packaged goods (CPG) companies. This partnership aims to create a new category of products at a time when market demand, cultural acceptance, and desire for cannabinoids are on the rise around the world.
Key Points:
- Nalu Bio is the first company to offer combinations of cannabinoids and bioactives to address pain, anxiety, sleep, and weight management.
- According to Nutrition Business Journal's 2023 Supplement Report, combination sales are expected to surpass single ingredient supplement sales this year.
- In tandem with PIPA, Nalu Bio will leverage predictive AI modeling to identify the optimal combinations of cannabinoids with unique bioactives such as vitamins, protein, fiber, antioxidants, probiotics, and superfoods.
- Like vitamins, not only can chemically-derived cannabinoid combinations address multiple health needs, but they can scale responsibly, safely, and sustainably.
